Human isotope fractional absorption studies comparing chelated Magnesium Glycinate vs. Citrate vs. 4% Oxide, CYP2R1/CYP27B1 magnesium-dependent Vitamin D3 activation trials, and Metformin-induced Vitamin B12 holotranscobalamin depletion. Explore 4,327 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
As HFO-1234ze pMDI has a near-zero GWP, it represents a compelling, environmentally conscious alternative propellant for use in pMDI devices for treatment of chronic breathing disease.
Semaglutide treatment improved cardiorenal outcomes versus placebo in people with T2D, regardless of prior CVD and baseline BMI.
Results indicate that in addition to objective outcomes of improved AHI, hypoxic burden associated with OSA, and heart and blood vessel risk factors, people with OSA reported benefits in symptoms, functioning, and HRQoL...
Mean duration of Q-TWiST was 21.07 (zanubrutinib) versus 18.67 months (ibrutinib; difference: 2.40 months; 95%CI: 1.9-2.9; p <.001).
Combining molecular and clinico-pathologic factors enhances prognostic information.
In vessels with angiographically intermediate coronary lesions, angiographic lesion complexity may modulate the long-term efficacy of the guidance modality, with a potential benefit of OCT in complex lesions and FFR in...
Ibrutinib 560 mg, combined with BR, consistently improves PFS across the ibrutinib exposure range evaluated.
The absence of a relation between the RR trajectory and posttransplant outcomes stresses that using RR as a standalone criterion for kidney discard is not justified and may lead to unnecessary discard.
Regardless of the presence or number of self-reported atopic comorbidities, 16 weeks of tralokinumab treatment improved AD severity in adults and adolescents.
Mean ferritin concentrations were above normal throughout the study, regardless of iron overload status.
This longitudinal analysis of PROs in a large trial of breast and boost radiotherapy demonstrates an overall decrease in the number of patient-reported moderate/marked AEs up to 5-years following radiotherapy.
For all induction ER endpoints, tumor necrosis factor (TNF)-naive patients had significantly higher probability of a favorable outcome at end of induction compared to TNF-experienced patients.
Most initial nonresponders to IV RZB induction who received 12W of extended RZB treatment demonstrated improved clinical and.
More than half of the patients that were continent at baseline remained continent during follow up while incontinent patients showed a variable course.
Furthermore, cross-reactivity by identification of anti-JN.1 and anti-Wuhan IgA was also observed.
On the basis of interim findings and the principle of nonmaleficence, the trial should be terminated.
No new safety signals were observed across subgroups.
There were 4 fatalad verse events in the ibrutinib arm due to infection.
Semaglutide resulted in a similar reduction in BW across frailty subgroups but greater improvements in HF-related symptoms.
For ARPI-naïve patients who did not receive darolutamide in ARASENS, postprogression survival was longer with subsequent ARPI versus taxane treatment, but OS remained shorter in comparison to the darolutamide group.
TRT increased circulating neutrophils and monocytes and decreased lymphocytes and platelets in men with hypogonadism.
Tirzepatide was effective in full symptom relief of obstructive sleep apnea syndrome and metabolic dysfunction-associated steatohepatitis.
Triple FDC of DAPA + SITA + MET IR demonstrated superior efficacy in achieving glycaemic control in patients with T2DM compared to dual FDC.
During an AHF hospitalization, women received lower doses of loop diuretic agents and achieved less weight loss with slightly lower diuretic response compared with men, despite similar symptom relief and postdischarge outcomes.
The PROVENT ToP model estimated the variant-specific observed efficacies from SUPERNOVA for 3 and 6 months post any dose with Lin's concordance of 0.86 and 0.75, respectively.
When comparing the two treatment groups, PPAR-γ and ADIPO expression were significantly higher in the Met + EZY group during T2 and T3 compared to the Met group (p < 0.001).
Survival improvements were related to changes in clinical management, such as administration of anti-GD2 immunotherapy or the start of the LINES clinical trial (EudraCT 2010-021396-81, registered on 15 June 2011;...
However, more long-term randomized controlled trials are needed to confirm these findings and further assess its effectiveness.
The preclinical investigations provide a strong foundation for ongoing and future clinical trials, emphasizing the need to tailor TCE-based combination therapies to maximize efficacy while minimizing toxicity in lymphoma...
SERM therapy is associated with significantly improved levels of TT, LH, and FSH in hypogonadal men compared to placebo, and significantly enhanced levels of LH and FSH compared to T gel.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
